Crossref
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
AME Clinical Trials Review · 2026-04 · 4 · 20-20
DOI: 10.21037/actr-26-0001 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Frida Bugge Askeland und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Askeland, F. B., & Schjesvold, F. (2026). Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”. AME Clinical Trials Review, 4, 20-20. https://doi.org/10.21037/actr-26-0001
Vancouver
Askeland FB, Schjesvold F. Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”. AME Clinical Trials Review. 2026;4:20-20. doi:10.21037/actr-26-0001
BibTeX
@article{Askeland2026,
author = {Askeland, Frida Bugge and Schjesvold, Fredrik},
title = {Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {20--20},
doi = {10.21037/actr-26-0001}
}
EUVIMED